Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab

Abstract Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn. She had no personal or family history of psoriasis or c...

Full description

Bibliographic Details
Published in:	Dermatology and Therapy
Main Authors:	Erin Bartholomew, Bo-Young Chung, Mitchell Davis, Samuel Yeroushalmi, Mimi Chung, Marwa Hakimi, Tina Bhutani, Wilson Liao
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-09-01
Subjects:	Guttate psoriasis Guselkumab Sunburn Anti-IL23 Monoclonal antibody Remission
Online Access:	https://doi.org/10.1007/s13555-023-01013-y

Similar Items

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
by: Grace C. Brummer, BS, et al.
Published: (2017-09-01)

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
by: Maryia Zhdanava, et al.
Published: (2024-12-01)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-03-01)

Ayurvedic Management of Kitibhakushta (Guttate Psoriasis) – A Case Report
by: Sourabh Deshmukh, et al.
Published: (2024-12-01)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019-06-01)

Psoriasis gutata pada laki-laki dewasa: sebuah kasus jarang (Adult males with guttate psoriasis: a rare case)
by: Nanda Earlia, et al.
Published: (2023-03-01)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024-03-01)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-09-01)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024-12-01)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022-03-01)

SARS‐CoV‐2 and guttate psoriasis: A case report and review of literature
by: Elrazi Ali, et al.
Published: (2021-07-01)

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024-10-01)

Histone Deacetylase 1 and Sirtuin 1 Expression in Psoriatic Skin: A Comparison between Guttate and Plaque Psoriasis
by: Young-Ji Hwang, et al.
Published: (2020-08-01)

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020-01-01)

Microbiota differences of skin and pharyngeal microbiota between patients with plaque and guttate psoriasis in China
by: Jingjin Hu, et al.
Published: (2022-08-01)

New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette–Guerin
by: Chih-Tsung Hung, et al.
Published: (2012-09-01)

Successful treatment of pyoderma gangrenosum with guselkumab
by: Sofia Botvid, et al.
Published: (2025-03-01)

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy
by: Andrew Blauvelt, et al.
Published: (2024-09-01)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
by: Ricardo Ruiz-Villaverde, et al.
Published: (2022-09-01)

Current advances in biological therapy of psoriasis: efficacy of guselkumab in real clinical practice
by: O. V. Zhukova, et al.
Published: (2022-03-01)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024-07-01)

Guselkumab for the treatment of psoriasis – evidence to date
by: Miguel Nogueira, et al.
Published: (2019-07-01)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
by: Ahmed Bagit, BSc, et al.
Published: (2023-09-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
by: Leyla Baykal Selçuk, et al.
Published: (2025-04-01)

Analysis of microbial flora in skin lesions of primary acute guttate psoriasis
by: Jia ZHANG, et al.
Published: (2022-10-01)

Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2025-07-01)

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment
by: Yuan X, et al.
Published: (2024-02-01)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
by: Ana-Maria Orbai, et al.
Published: (2023-09-01)

Pediatric psoriasis: A case series of unusual presentation
by: Bhavya Sangal, et al.
Published: (2025-11-01)

A case of concomitant hidradenitis suppurativa and psoriasis successfully treated with guselkumab in a patient with Down syndrome
by: Simge Ünal, et al.
Published: (2024-06-01)

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms
by: Annunziata Dattola, et al.
Published: (2025-09-01)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
by: Marloes E. van Muijen, et al.
Published: (2022-08-01)

Reactivation of latent hepatitis B infection during immunosuppressive therapy with guselkumab for plaque psoriasis: a case report
by: Elena Franchi, et al.
Published: (2023-12-01)

Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report
by: Nana Luo, et al.
Published: (2025-12-01)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01)

Based on Gene Expression Analysis: Low-Density Neutrophil Expression Is a Characteristic of the Fast Responders Treated With Guselkumab for Psoriasis
by: Jiajing Lu, et al.
Published: (2022-05-01)

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
by: Byung Soo Kim, et al.
Published: (2023-09-01)

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy
by: Andrew Blauvelt, et al.
Published: (2024-09-01)

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
by: Jianfeng Zheng, et al.
Published: (2023-12-01)